Articles tagged with Cancer Medication
USC researchers have discovered an oral cancer drug, zebularine, that can reactivate silenced genes and reduce tumor size in mice. The study found that zebularine is effective in both intraperitoneal and oral administration routes.
A study found that higher plasma folate levels were associated with lower risk of breast cancer, while higher plasma vitamin B6 levels increased breast cancer risk. Plasma vitamin B12 levels inversely associated with breast cancer risk among premenopausal women. Cystic fibrosis patients may have an increased risk of digestive tract can...
Researchers at Cyclis Pharmaceuticals have discovered a new mechanism for treating cancer, involving the activation of the E2F1 protein with small molecule drugs. The findings, published in the Proceedings of the National Academy of Sciences, show that this approach can selectively kill cancer cells while sparing normal cells.
Researchers are working towards individualized treatments using DNA chip technology to analyze gene expression and detect host genetic polymorphisms. This approach aims to optimize drug selection and doses at a molecular level, reducing toxicity and improving patient outcomes for childhood acute lymphoblastic leukemia.
Researchers are using toxicogenomics to study the genetic and protein changes in individual breast cancer cells to assign effective drug treatments. This approach allows for more precise treatment options and earlier detection of toxicity, enabling doctors to make informed decisions.
A new phthalocyanine compound, Pc 4, targets cancerous cells preferentially, leaving healthy tissue alone. The treatment uses laser light to activate the drug, producing forms of oxygen that kill cancer cells and break down tumors.
Researchers found that a vitamin A derivative, 9-cis retinoic acid, increased RAR-_ gene expression and reduced precancerous lesions in former smokers. While promising, the treatment also showed side effects, and further studies are needed to determine its effectiveness.
Researchers at Georgetown University Medical Center found that malfunctioning beta-spectrin genes cause defects in embryonic development and interfere with TGF-beta functions, which are crucial for growth and cancer progression. This discovery has important implications for human disease research and treatment.
Researchers found that the arginine variant of p53 is more efficient at killing cells and travels out of the nucleus to function in the mitochondria. This discovery could lead to personalized cancer treatment by tailoring therapy based on a patient's p53 variant type.
Dutch researchers found a possible link between IVF and eye cancer in children. The study suggests that IVF children are 5-7 times more likely to develop retinoblastoma, a rare form of childhood eye cancer. Researchers are now calling for closer follow-up and monitoring of IVF-conceived children.
A study found that intensive pharmacy consultations reduced drug-related deaths by 8% among patients taking high-risk medications, while lower hospitalization rates were observed in certain groups receiving any type of consultation. The research implies that pharmacist interventions can substantially reduce medication-related mortality.
Researchers found that cancer cells can migrate through protein matrices by reverting to a more rounded shape, allowing them to continue moving even when inhibitors are present. This 'salvage' pathway could be targeted by new drugs to combat cancer spread.
Researchers have discovered a genetic mutation in the DKC1 gene that causes a rare, fatal X-linked recessive disease characterized by premature aging, bone marrow failure, and increased cancer risk. The study suggests that ribosome dysfunction, rather than telomerase impairment, is the primary cause of this syndrome.
Researchers have identified a mutated form of the enzyme PDGFRA, which is found in many body tissues and may trigger gastrointestinal stromal tumors. The study validates a novel molecular technology that can be used to find additional targets for cancer treatments.
Researchers found that tamoxifen stimulation increased mature eggs and embryos compared to natural cycle IVF, with one patient already giving birth to twins. A larger study is planned to include low amounts of FSH for additional benefits.
Researchers have discovered that combining Avastin with chemotherapy provides superior treatment for advanced colorectal cancer, increasing median survival by 8.3 months and response rates. The study's findings suggest a more effective and less toxic option for patients with this devastating form of cancer.
Researchers at Brigham Young University have successfully tested a new method to concentrate the impact of cancer drugs on specific tissues, sparing healthy areas. The method uses tiny water-soluble plastic particles and ultrasound to release the drug at the tumor site, significantly reducing tumor size in laboratory animals.
Researchers inserted a firefly gene into mice with cancer, allowing them to detect cell death in real-time. The technology uses luciferase to emit light only when cells start dying, enabling rapid testing of new drugs for cancer and other diseases.
Researchers investigated the association between alcohol consumption and lung cancer risk, finding no statistically significant link. The Journal of National Cancer Institute also published studies on body surface area-based dosing for anticancer drugs and carbohydrate binding protein's potential to inhibit tumor growth.
The Wistar Institute's MAb425 antibody has shown promising results in a Drexel University trial, with three high-grade tumor patients alive after five years and eight lower-grade tumor patients surviving for 56 months or longer.
Researchers discovered that tamoxifen-resistant breast cancer cells alter their traits and become responsive to Herceptin and other HER-2 targeted drugs. A new GlaxoSmithKline drug, GSK572016, shows promise in shrinking tumors resistant to both tamoxifen and Herceptin.
A new gene profiling technique could help predict which breast cancer patients will respond to hormonal therapies and which will require additional chemotherapy. The study aims to identify the cellular programs that must be engaged or shut off for aromatase inhibitors to be successful.
Researchers at Dana-Farber Cancer Institute found that combination therapy of cytarabine, daunorubicin, and Mylotarg achieved complete remission in 83% of evaluable participants. The treatment was well-tolerated, with no significant increase in side effects.
A Phase II study of CC-5013, a thalidomide-like compound, has shown significant anti-myeloma activity with measurable responses in about 50 percent of evaluable patients. The drug has been well tolerated, with evidence that the daily dosing regimen has fewer side effects than the twice daily schedule.
In a Phase II clinical trial, VELCADE (bortezomib) produced partial responses in 32% of patients with relapsed or refractory myeloma. The overall response rate was 35%, with some patients continuing to show positive responses nearly a year after treatment.
A new 'designer' drug has shown activity in treating acute myeloid leukemia (AML), with 13 of 15 patients experiencing reductions in abnormal white blood cell counts. The experimental compound targets a specific genetic flaw, offering a more targeted approach to conventional chemotherapy drugs.
The Salk Institute and SUGEN scientists have created a detailed catalog of the 518 protein kinase genes encoded by the human genome. This comprehensive mapping will enable the development of new drugs targeting kinases, offering an alternative to standard chemotherapy for specific types of cancer.
A phase I trial using rViscumin administered intravenously has begun in Hanover and Nantes, France, with preliminary results showing immune system responses to the drug. The trials are part of further Phase I studies being considered, which will determine the clinical significance of rViscumin.
Research in mice found that rapamycin combined with radiation treatment delayed the regrowth of glioblastoma multiforme (GBM) human tumors by an average of 19 days. Rapamycin inhibits the activity of mTOR, a protein promoting tumor growth, and its combination with radiation may enhance chemotherapy efficacy.
A Phase I study of the novel anti-angiogenic drug SU011248 showed promising results in patients with advanced cancers that had failed to respond to other therapies. The drug demonstrated activity in a range of tumour types, including renal and gastrointestinal cancers, but did not show efficacy against brain metastases.
Researchers found that inhibiting PDGF signalling increases tumour uptake of cytotoxic drugs without increasing toxicity. Combination therapies with Glivec and other drugs induced better anti-tumour effects in animal models, suggesting a new strategy for improving drug treatment for cancer patients.
Researchers use firefly protein to visualize cellular communication pathways in mice, revealing potential for non-invasive cancer treatment and disease research. This breakthrough enables scientists to watch proteins in their natural setting, improving understanding of human diseases.
A phase II clinical trial shows the oral combination of thalidomide and dexamethasone reduces tumor size by 50% or more in 64% of newly diagnosed multiple myeloma patients. This treatment alternative offers a promising solution to chemotherapy's side effects, including nausea, vomiting, and hair loss.
A new strategy in cancer treatment involves using genetic information to guide drug delivery, allowing for more targeted and efficient treatments. The approach uses nucleic acid-triggered catalytic drug release, recognizing and responding to unique cancerous sequences to deliver potent anticancer drugs.
A new trial shows that high-dose chemotherapy has no significant benefits for women with severe breast cancer. However, molecularly targeted drugs in combination with chemotherapy show promising results.
Early results of North American trials of oxaliplatin show a 70% delay in tumour progression and significant improvement in symptoms for patients with advanced bowel cancer. The US FDA has approved the drug for use in these patients.
Professor Edzard Ernst urges oncologists to be open to alternative medicines, as desperation drives patients to try anything. He warns that some therapies can be dangerous and advises patients to consult with healthcare professionals before trying new treatments.
Researchers have discovered a novel compound that kills bad immune cells while leaving healthy ones intact, offering hope for safer and more effective treatments for lupus. The compound, Bz-423, targets a protein in immune cells' mitochondria, showing promise in treating autoimmune diseases and potentially some types of cancer.
The American Association for Cancer Research (AACR) is calling on the FDA to accelerate the development and approval of chemopreventive agents for precancerous cells. Emerging technologies have improved detection capabilities, but drug approvals remain limited due to concerns about treatment efficacy in high-risk populations.
A study in the Journal of the National Cancer Institute found that women undergoing prophylactic bilateral mastectomy often overestimate their breast cancer risk. Meanwhile, a separate study uncovered no association between antiperspirant use and increased breast cancer risk. Furthermore, researchers identified a serum protein expressi...
Researchers found that hormones bind to specific receptors in cells, recruiting co-activators to regulate gene expression and alter protein production. This process enables a vast range of protein diversity from relatively few genetic sources.
A team of researchers from Duke University has made significant breakthroughs in understanding the mechanism of FTase, a key player in cancer development. The study revealed that FTase doesn't release its product until another substrate molecule arrives, suggesting a new role for the enzyme beyond molecular seamstressing.
Healthy, nondividing cells have a biochemical switch that triggers apoptosis when inactivated by deamidation of Bcl-xL protein. This discovery suggests that tumor cells with the same switch may be resistant to chemotherapy drugs.
Sporn's groundbreaking research on chemoprevention has revolutionized the field of cancer prevention, exploring novel approaches to prevent or treat cancer. His work has led to strategies with vast potential for reducing cancer incidence and death, and continues to inspire new directions in cancer prevention research.
Researchers have identified three new genes in a rhesus monkey rhadinovirus with high structural similarity to those in human herpesvirus-8, paving the way for future studies using recombinant viruses. The goal is to develop targeted drug therapies against specific KSHV genes to prevent virus spread and cancer induction.
Dr. Michael Sporn, a renowned cancer researcher, has made significant contributions to cancer prevention through his work on chemoprevention and the development of new strategies to reduce cancer incidence and death. He is recognized for his pioneering studies on the role of Vitamin A and retinoids in cancer prevention.
The study tracked the movement of individual cancer cells in real-time using computer automation. The research revealed similarities between breast and skin cancer strains, including oscillation and burrowing into tissue.
Researchers conducted a Phase I clinical trial of endostatin, showing that it decreases blood flow to tumors and promotes the death of cancer cells. The study also found minor anti-tumor activity in two patients, but no long-term responses were seen.
The National Functional Genomics Project aims to track genetic changes in cancer to design more effective therapeutic agents and understand hereditary and environmental influences. Moffitt's expertise in translational research will accelerate the translation of molecular medicine into early detection and clinical treatment.
Researchers discovered tetrathiomolybdate (TM) inhibits tumor angiogenesis by reducing copper levels and blocking NFkB signaling pathway. TM suppressed tumor growth in mice with aggressive breast cancer, prevented blood vessel formation, and induced disease-free survival.
A study of 270 patients found that bladder cancer recurrence rates increased with each episode, with the average time to second and third recurrences decreasing by 15 and 13 months respectively. Patients whose original tumors tested positive for the Ki-67 marker were at higher risk for first recurrence.
Researchers at Penn State have identified a protein, km23, that is defective in nearly half of human cancer tissues. Alterations in this protein disrupt cell signaling, leading to tumor growth and spreading. The team hopes to develop drugs targeting km23 to prevent tumor progression and diagnose specific cancers.
A recent analysis of eight PC-SPES lots revealed widespread contamination with indomethacin and diethylstilbestrol, two potent synthetic compounds that undermine the supplement's anticancer potency. The study suggests that the contaminated batches had significantly reduced anticancer activity.
Researchers at Cedars-Sinai Medical Center found that a cancer drug caused a virus to mutate so much it could no longer reproduce, becoming extinct. The treatment increases mutations in viral genomes, making it a promising approach to combat viruses.
A study has characterized a significant family of signaling proteins in the human genome, identifying 60 previously unknown protein kinases. The comprehensive analysis provides valuable insights into understanding the relationships between protein kinase structures and functions.
Researchers at University College London have discovered a potential new cancer treatment using compounds found in cola beverages, coffee, tea, and chocolate. The compounds block the operation of a key enzyme linked to cell growth and blood clotting.
A study found that St. John's wort significantly lowers blood levels of irinotecan's active metabolite SN-38 by 42%, decreasing detoxification and reducing overall antitumor activity. Patients receiving chemotherapeutic treatments with St. John's wort may need to increase drug dosage.
A synthetic compound called oxomate has been developed to target breast cancer, with promising results in animal tests and potential for a once-a-day pill or vitamin component. If confirmed, oxomate could offer an alternative to current treatments and provide benefits to those at high risk of cancer
Researchers at UW-Madison have identified genetic elements in soil-dwelling bacteria that produce potent anticancer agents. The discovery enables mass production and manipulation of these chemicals, offering a promising alternative to existing treatments.
A new study from the International Collaborative Ovarian Neoplasm (ICON) Collaborators found that paclitaxel plus carboplatin produces similar effectiveness to other treatments for women with ovarian cancer, but with more serious side effects. Carboplatin may be considered a preferred treatment option due to its better toxicity profile.